Cantargia strengthens organisation with CFO
Cantargia AB (“Cantargia”) today announces that the company is strengthening its organisation with a Chief Financial Office, Bengt Jöndell. Mr Jöndell has more than 25 years’ experience from various industrial finance functions, mainly in pharmaceuticals and biotechnology.
Bengt Jöndell graduated with an M.Sc. in Economics and Business from Lund University and an M.Sc. in Engineering from the Faculty of Engineering at Lund University. Since then he has gained extensive experience mainly in various areas of the pharmaceutical and biotech industries and at other medium-sized companies. His previous positions include various roles in the Pharmacia group and senior financial positions at Inpac AB, Bonesupport AB and BTJ Group. Over the past year he has been Acting CFO at Enzymatica AB. Bengt Jöndell will take up his post at Cantargia on 22 May 2017.
“As Cantargia continues to develop a need has arisen to strengthen our management team with a CFO”, Göran Forsberg, CEO of Cantargia, says. “Bengt has a background and skills profile that fit in very well with Cantargia, and we look forward to working with him”.
“With my experience from several pharmaceutical-related businesses, it feels very exciting and inspiring to become a part of Cantargia’s organisation”, Bengt Jöndell says.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 19 May 2017, at 10:15.
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.
Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.